WIA
XBI icon

Wetzel Investment Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Wetzel Investment Advisors’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-500
Closed -$47.4K – 906
2024
Q2 		$47.4K Hold
500
– – 0.03% 246
2024
Q1 		$41.7K Hold
500
– – 0.02% 277
2023
Q4 		$45K Buy
+500
New +$37.1K 0.03% 258

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Wetzel Investment Advisors's XBI Position: Q3 2024 in Review

Wetzel Investment Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2024, closing a stake of 500 shares — an estimated $47.4K sold.

Wetzel Investment Advisors first reported a position in XBI in Q4 2023 and held it in 3 quarters. The position peaked at $47.4K in Q2 2024. 770 funds tracked by Wall St. Rank hold XBI as of Q3 2024.

  • Wetzel Investment Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2024 after selling out during the quarter.
  • Wetzel Investment Advisors sold 500 State Street SPDR S&P Biotech ETF shares in Q3 2024, an estimated $47.4K.
  • Wetzel Investment Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and held it in 3 quarters.
  • Wetzel Investment Advisors's State Street SPDR S&P Biotech ETF position peaked at $47.4K in Q2 2024.
  • 770 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.

Based on Wetzel Investment Advisors's 13F filing for Q3 2024, filed 29 Oct 2024.